--- title: HB 227. Putting Georgia's Patients First Act; enact collection: bills id: 2025-2026/hb227 cite_as: HB 227, 2025-2026 Regular Session (Ga.) canonical_url: https://georgiacommons.org/bills/2025-2026/hb227 md_url: https://georgiacommons.org/bills/2025-2026/hb227.md text_url: https://georgiacommons.org/bills/2025-2026/hb227/text source_url: https://www.legis.ga.gov/legislation/69832 date: 2025-02-28 status: engrossed corpus_version: bills-2026-09-13 license: Public record of the Georgia General Assembly, via LegiScan; see about.md publisher: Georgia Commons, an independent project of Georgia Civic Data. Not the State of Georgia. Not legal advice. up: https://georgiacommons.org/bills/2025-2026.md previous: https://georgiacommons.org/bills/2025-2026/hb226.md next: https://georgiacommons.org/bills/2025-2026/hb228.md index: https://georgiacommons.org/bills/index.md omitted: votes and history omitted_chars: 493 omitted_url: https://georgiacommons.org/bills/2025-2026/hb227.md?full=1 bill_number: HB 227 session: 2025-2026 Regular Session session_slug: 2025-2026 chamber: House bill_type: bill status_date: 2025-02-27 last_action: Senate Read and Referred sponsors: - Robert Dickey - Matt Reeves - Brian Prince - Leesa Hagan - Trey Rhodes - Eric Bell text_version: Comm Sub has_text: true legiscan_url: https://legiscan.com/GA/bill/HB227/2025 upstream_id: 1955727 summaries_model: claude-sonnet-5 topic_tags: - medical cannabis - low THC oil - cannabis regulation - patient registry - drug penalties --- # HB 227. Putting Georgia's Patients First Act; enact ## Text House Bill 227 (COMMITTEE SUBSTITUTE) By: Representatives Dickey of the 134th, Reeves of the 99th, Prince of the 132nd, Hagan of the 156th, Rhodes of the 124th, and others A BILL TO BE ENTITLED AN ACT To amend various provisions of the Official Code of Georgia Annotated so as to rename low THC oil as medical cannabis; to amend Chapter 12 of Title 16, Article 2 of Chapter 13 of Title 16, and Article 1 of Chapter 2A of Title 31 of the Official Code of Georgia Annotated, relating to offenses against the public health and morals, regulation of controlled substances, and general provisions relative to the Department of Public Health, respectively, so as to clarify and revise criminal penalties; to clarify and revise exemptions to criminal penalties; to revise the duties of the Georgia Access to Medical Cannabis Commission; to provide for the provision of certain information by licensees; to provide limitations on the provision of such information; to exclude the lawful possession and control of medical cannabis from the provisions of the Georgia Controlled Substances Act; to revise the existing diagnosed conditions for which a medical cannabis registration card can be issued; to provide for conforming changes; to provide definitions; to provide a short title; to provide for related matters; to repeal conflicting laws; and for other purposes. BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA: PART I SECTION 1-1. This Act shall be known and may be cited as the 'Putting Georgia's Patients First Act." PART II SECTION 2-1. Title 2 of the Official Code of Georgia Annotated, relating to agriculture, is amended by replacing "low THC oil" and "Low THC oil" with "medical cannabis" and "Medical cannabis", respectively, wherever such terms occur in: (1) Code Section 2-11-36, relating to seeds used in production of low THC oil; (2) Code Section 2-23-9.2, relating to consumable hemp products, packaging, advertising, and distribution; and (3) Code Section 2-23-9.3, relating to location of retail establishments selling or distributing consumable hemp products. SECTION 2-2. Article 9 of Chapter 12 of Title 16 of the Official Code of Georgia Annotated, relating to access to medical cannabis, is amended by replacing "low THC oil" and "Low THC oil" with "medical cannabis" and "Medical cannabis", respectively, and by replacing "Low THC Oil Patient Registry" with "Medical Cannabis Patient Registry", wherever such terms occur in: (1) Code Section 16-12-201, relating to prohibition against producing, growing, manufacturing, or dispensing low THC oil or products; (2) Code Section 16-12-203, relating to powers, duties, and responsibilities of the Georgia Access to Medical Cannabis Commission; (3) Code Section 16-12-204, relating to nontransferable designated university licenses to produce low THC oil and products, research and reporting of collected information, and license revocation; (4) Code Section 16-12-206, relating to annual, nontransferable dispensing license, adoption of rules, and fees; (5) Code Section 16-12-210, relating to powers, duties, and responsibilities of the Georgia Access to Medical Cannabis Commission, no undue burden on patients, and remission of fees; (6) Code Section 16-12-211, relating to class 1 production licenses, application fees, revocation, and limitation on ownership; (7) Code Section 16-12-212, relating to class 2 production licenses, application fee, revocation, and limitation on ownership; (8) Code Section 16-12-213, relating to tracking system requirements; (9) Code Section 16-12-216, relating to Bureau of Investigation, Access to Medical Cannabis Commission, and Composite Medical Board to jointly establish procedures to ensure compliance; (10) Code Section 16-12-217, relating to on-demand access to facilities, provision of samples, testing, and secured transportation; (11) Code Section 16-12-224, relating to limitation on ownership by member or former member of the Georgia Access to Medical Cannabis Commission, limitation on physician's involvement, and identification when contributing to political campaigns; (12) Code Section 16-12-225, relating to criminal offenses and penalties; (13) Code Section 16-12-226, relating to sales and use taxes applicable; (14) Code Section 16-12-230, relating to requirements for dispensing low THC oil and products; (15) Code Section 16-12-231, relating to exemptions from arrest, prosecutions, or penalty; (16) Code Section 16-12-233, relating to contracts not against public policy; (17) Code Section 16-12-234, relating to unlawful ways to ingest low THC oil or products; (18) Code Section 16-12-235, relating to research in compliance with federal regulations; and (19) Code Section 16-12-235.1, relating to possession of low THC oil and products by colleges and universities for research purposes, permitting requirements, and inspection. SECTION 2-3. Article 1 of Chapter 2A of Title 31 of the Official Code of Georgia Annotated, relating to general provisions relative to the Department of Public Health, is amended in Code Section 31-2A-18, relating to low THC oil patient registry, registration cards, reports, waiver forms, and annual review and recommendations, by replacing "low THC oil" and "Low THC oil" with "medical cannabis" and "Medical cannabis", respectively, and by replacing "Low THC Oil Patient Registry" with "Medical Cannabis Patient Registry" wherever such terms occur. SECTION 2-4. Chapter 1 of Title 51 of the Official Code of Georgia Annotated, relating to general provisions relative to torts, is amended in Code Section 51-1-29.6, relating to liability of healthcare institutions and providers regarding low THC oil, by replacing "low THC oil" and "Low THC oil" with "medical cannabis" and "Medical cannabis", respectively. PART III SECTION 3-1. Chapter 12 of Title 16 of the Official Code of Georgia Annotated, relating to offenses against public health and morals, is amended by revising Article 8, relating to regulation of low THC oil, as follows: "ARTICLE 8 16-12-190. As used in this article, the term: (1) 'Medical cannabis' 'low THC oil' means an oil that contains an amount of cannabidiol and not more than 5 percent by weight of tetrahydrocannabinol, tetrahydrocannabinolic acid, or a combination of tetrahydrocannabinol and tetrahydrocannabinolic acid which does not contain plant material exhibiting the external morphological features of the plant of the genus Cannabis. Such term shall not mean include: (A) Goods products approved by the federal Food and Drug Administration under Section 505 of the federal Food, Drug, and Cosmetic Act; or (B) Hemp or hemp products, as such terms are defined in Code Section 2-23-3. (2) 'Product' shall have the same meaning as set forth in Code Section 16-12-200. 16-12-191. (a)(1) Notwithstanding any provision of Chapter 13 of this title, it shall be lawful for any person to possess, purchase, or have under his or her control 20 fluid ounces or less of low THC oil medical cannabis or a product or products containing an equivalent amount of medical cannabis if such substance medical cannabis or product or products is in a pharmaceutical container labeled by the manufacturer indicating the percentage of tetrahydrocannabinol therein and: (A) Such person is registered with the Department of Public Health as set forth in Code Section 31-2A-18 and has in his or her possession a registration card issued by the Department of Public Health; or (B) Such person has in his or her possession a registration card issued by another state that allows the same possession of low THC oil medical cannabis as provided by this state's law; provided, however, that such registration card shall not be lawful authority when such person has been present in this state for 45 days or more. (2) Notwithstanding any provision of Chapter 13 of this title, any person who possesses, purchases, or has under his or her control 20 fluid ounces or less of low THC oil medical cannabis or a product or products containing an equivalent amount of medical cannabis without complying with paragraph (1) of this subsection shall be punished as for a misdemeanor. (b)(1) Notwithstanding any provision of Chapter 13 of this title, it shall be lawful for any person to possess, purchase, or have under his or her control 20 fluid ounces or less of low THC oil medical cannabis or a product or products containing an equivalent amount of medical cannabis if: (A) Such person is involved in a clinical research program being conducted by the Board of Regents of the University System of Georgia or any authorized clinical trial or research study in this state or their its authorized agent as: (i) A program participant; (ii) A parent, guardian, or legal custodian of a program participant; (iii) An employee of the board of regents designated to participate in the research program; (iv) A program agent; (v) A program collaborator and their its designated employees; (vi) A program supplier and their its designated employees; (vii) A program physician; (viii) A program clinical researcher; (ix) Program pharmacy personnel; or (x) Other program medical personnel; and (B) Such substance medical cannabis or product or products is in a pharmaceutical container labeled by the manufacturer indicating the percentage of tetrahydrocannabinol therein. (2) Notwithstanding any provision of Chapter 13 of this title, any person who possesses, purchases, or has under his or her control 20 fluid ounces or less of low THC oil medical cannabis or a product or products containing an equivalent amount of medical cannabis without complying with subparagraphs (A), (B), and (C) of paragraph (1) of this subsection shall be punished as for a misdemeanor. (c) Notwithstanding any provision of Chapter 13 of this title, any person having possession of, purchasing, or having under his or her control more than 20 fluid ounces of low THC oil but less than 160 fluid ounces of low THC oil medical cannabis or a product or products containing an equivalent amount of medical cannabis or who manufactures, distributes, dispenses, sells, purchases, or possesses with the intent to distribute low THC oil medical cannabis shall be guilty of a felony and, upon conviction thereof, shall be punished by imprisonment for not less than one year nor more than ten years, a fine not to exceed $50,000.00, or both. (d) Notwithstanding any provision of Chapter 13 of this title, any person who sells, manufactures, delivers, brings into this state, purchases, or has possession of 160 or more fluid ounces of low THC oil medical cannabis or a product or products containing an equivalent amount of medical cannabis shall be guilty of the felony offense of trafficking in low THC oil medical cannabis and, upon conviction thereof, shall be punished as follows: (1) If the quantity of low THC oil medical cannabis is at least 160 fluid ounces but less than 31,000 fluid ounces, or the product or products contain an equivalent amount of medical cannabis, by imprisonment for not less than five years nor more than ten years and a fine not to exceed $100,000.00; (2) If the quantity of low THC oil medical cannabis is at least 31,000 fluid ounces but less than 154,000 fluid ounces, or the product or products contain an equivalent amount of medical cannabis, by imprisonment for not less than seven years nor more than 15 years and a fine not to exceed $250,000.00; and (3) If the quantity of low THC oil medical cannabis is 154,000 or more fluid ounces, or the product or products contain an equivalent amount of medical cannabis, by imprisonment for not less than ten years nor more than 20 years and a fine not to exceed $1 million. (e) Subsections (c) and (d) of this Code section shall not apply to a person involved in a research program being conducted by the Board of Regents of the University System of Georgia or its authorized agent as an employee of the board of regents designated to participate in such program, a program agent, a program collaborator and their its designated employees, a program supplier and their its designated employees, a physician, clinical researcher, pharmacy personnel, or other medical personnel. (f) Subsections (c) and (d) of this Code section shall not apply to a designated university, pharmacy, or licensee under Article 9 of Chapter 12 of Title 16, provided that such possession, purchase, control, sale, manufacturing, distribution, or dispensing is solely conducted in accordance with the provisions of Article 9 of Chapter 12 of Title 16. (g) Nothing in this article shall require an employer to permit or accommodate the use, consumption, possession, transfer, display, transportation, purchase, sale, or growing of marijuana in any form, or to affect the ability of an employer to have a written zero tolerance policy prohibiting the on-duty, and off-duty, use of marijuana, or prohibiting any employee from having a detectable amount of marijuana in such employee's system while at work." SECTION 3-2. Said chapter is further amended by revising Code Section 16-12-200, relating to definitions relative to access to medical cannabis, as follows: "16-12-200. As used in this article, the term: (1) 'Applicant' means a corporate entity applying for a license pursuant to this article. (2) 'Available capital' means corporate assets that are available to fund business operations in the event a license is awarded pursuant to Part 2 of this article. (3) 'Class 1 production license' means a license to produce and manufacture low THC oil medical cannabis and products issued pursuant to Code Section 16-12-211. (4) 'Class 2 production license' means a license to produce and manufacture low THC oil medical cannabis and products issued pursuant to Code Section 16-12-212. (5) 'Commission' means the Georgia Access to Medical Cannabis Commission created pursuant to Code Section 16-12-202. (6) 'Designated universities' means the University of Georgia and Fort Valley State University. (7) 'Designated university license' means a license issued by the commission pursuant to this article to a designated university to, separately or jointly, produce, manufacture, and purchase low THC oil medical cannabis and products in accordance with this article. (8) 'Dispense' means the sale or provision of low THC oil medical cannabis and products to registered patients by a dispensing licensee. (9) 'Dispensing license' means a specialty license issued by the State Board of Pharmacy or the commission pursuant to Code Section 16-12-206 to dispense low THC oil medical cannabis and products to registered patients. (10) 'Grow' means cultivating and harvesting cannabis for use in producing low THC oil medical cannabis and products. (11) 'Licensee' means any business, or owner of such business, with a valid license issued pursuant to this article. (12) 'Low THC oil' shall have the same meaning as set forth in Code Section 16-12-190. (13) 'Manufacture' means to process cannabis to produce low THC oil medical cannabis and products. (13) 'Medical cannabis' shall have the same meaning as set forth in Code Section 16-12-190. (14) 'Owner' means any person who directly or indirectly owns, actually or beneficially, or controls 5 percent or greater of interests of the applicant or any licensee. In the event that one person owns a beneficial right to interests and another person holds the voting rights with respect to such interests, then both shall be considered an owner of such interests. (15) 'Product' means low THC oil medical cannabis delivered through an oil, tincture, transdermal patch, lotion, or capsule, except as prohibited by Code Section 16-12-234, but not including hemp products, as such term is defined in Code Section 2-23-3, or any food products infused with low THC oil medical cannabis, including, but not limited to, cookies, candies, or edibles. (16) 'Registered patient' means an individual who is legally authorized to possess and use low THC oil medical cannabis and products pursuant to Code Section 31-2A-18. (17) 'Tracking system' means a seed-to-sale tracking system to track marijuana that is grown, processed, manufactured, transferred, stored, or disposed of and low THC oil medical cannabis and products that are transferred, stored, sold, dispensed, or disposed of pursuant to this article." SECTION 3-3. Said chapter is further amended in Code Section 16-12-203, relating to the powers, duties, and responsibilities of the Georgia Access to Medical Cannabis Commission, by adding a new paragraph to read as follows: "(10.1) To engage in public awareness activities concerning the medical cannabis program in this state and effective uses of medical cannabis and products, including, but not limited to, publishing materials and conducting outreach and public education activities to inform members of the public, law enforcement, and healthcare providers about the medical cannabis program in this state and the potential benefits that medical cannabis and products may have to eligible patients;" SECTION 3-4. Said chapter is further amended by revising Code Section 16-12-215, relating to limitations on locations, advertising or marketing prohibited, and information available to physicians, as follows: "16-12-215. (a) No licensee shall operate in any location, whether for cultivation, harvesting, and processing of marijuana or for processing, manufacturing, packaging, or distributing low THC oil medical cannabis or products, within a 3,000 foot radius of a covered entity, measured from property boundary to property boundary. No dispensing licensee may operate in any location within a 1,000 foot radius of a covered entity, measured from property boundary to property boundary. Notwithstanding the provisions of this subsection, local governments may, via use of existing zoning powers otherwise provided by law, allow dispensing licensees only to locate in places other than those provided in this subsection so long as such modification is needed to allow retail outlets to be established to service registered patients residing within such local jurisdiction. As used in this subsection, the term 'covered entity' means a public or private school; an early care and education program as defined in Code Section 20-1A-2; or a church, synagogue, or other place of public religious worship, in existence prior to the date of licensure of such licensee by the commission or State Board of Pharmacy. (b)(1) No licensee shall advertise or market low THC oil medical cannabis or products to registered patients or the public; provided, however, that a licensee shall be authorized to provide information regarding its low THC oil medical cannabis and products directly to physicians, registered patients, and caregivers; provided, further, that such information shall be subject to and meet the requirements set forth in the rules and regulations promulgated by the commission pursuant to paragraph (2) of this subsection. (2) The commission shall promulgate rules and regulations governing information provided by licensees under paragraph (1) of this subsection to ensure that such information: (A) Does not include medical claims that are unsupported by reliable scientific evidence; (B) Does not make any false or misleading claim; (C) Is not attractive to children or otherwise directly or indirectly targeted to children; and (D) Is not otherwise unfair and deceptive or harmful to the public." SECTION 3-5. Article 2 of Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to regulation of controlled substances, is amended in Code Section 16-13-21, relating to definitions, by revising paragraph (16) as follows: "(16) 'Marijuana' means all parts of the plant of the genus Cannabis, whether growing or not, the seeds thereof, the resin extracted from any part of such plant, and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds, or resin, but shall not include samples as described in subparagraph (P) of paragraph (3) of Code Section 16-13-25; shall not include the completely defoliated mature stalks of such plant, fiber produced from such stalks, oil, or cake, or the completely sterilized samples of seeds of the plant which are incapable of germination; and shall not include hemp or hemp products, as such terms are defined in Code Section 2-23-3, or medical cannabis or products, as such terms are defined in Code Sections 16-12-190 and 16-12-200, respectively, when in the possession or control of a person authorized to possess and control such medical cannabis or products under the provisions of Article 8 or Article 9 of Chapter 12 of this title. Such term shall not include products approved by the federal Food and Drug Administration under Section 505 of the federal Food, Drug, and Cosmetic Act." SECTION 3-6. Said article is further amended in Code Section 16-13-25, relating to Schedule I, by revising subparagraph (P) of paragraph (3) as follows: "(P) Tetrahydrocannabinol, tetrahydrocannabinolic acid, or a combination of tetrahydrocannabinol and tetrahydrocannabinolic acid which does not contain plant material exhibiting the external morphological features of the plant of the genus Cannabis, but not including such substance when found in hemp or hemp products, as such terms are defined in Code Section 2-23-3, or in medical cannabis or products, as such terms are defined in Code Sections 16-12-190 and 16-12-200, respectively, when in the possession or control of a person authorized to possess or control such medical cannabis or products under the provisions of Article 8 or Article 9 of Chapter 12 of this title. Tetrahydrocannabinols do not include products approved by the federal Food and Drug Administration under Section 505 of the federal Food, Drug, and Cosmetic Act;" SECTION 3-7. Article 1 of Chapter 2A of Title 31 of the Official Code of Georgia Annotated, relating to general provisions relative to the Department of Public Health, is amended in Code Section 31-2A-18, relating to Low THC Oil Patient Registry, registration cards, reports, waiver forms, and annual review and recommendations, by revising paragraph (3) of subsection (a) as follows: "(3) 'Condition' means: (A) Cancer, when such disease is diagnosed as end stage or the treatment produces related wasting illness or recalcitrant nausea and vomiting; (B) Amyotrophic lateral sclerosis, when such disease is diagnosed as severe or end stage; (C) Seizure disorders related to a diagnosis of epilepsy or trauma related head injuries; (D) Multiple sclerosis, when such disease is diagnosed as severe or end stage; (E) Crohn's disease; (F) Mitochondrial disease; (G) Parkinson's disease, when such disease is diagnosed as severe or end stage; (H) Sickle cell disease, when such disease is diagnosed as severe or end stage; (I) Tourette's syndrome, when such syndrome is diagnosed as severe; (J) Autism spectrum disorder, when such disorder is diagnosed for a patient who is at least 18 years of age, or severe autism, when diagnosed for a patient who is less than 18 years of age; (K) Epidermolysis bullosa; (L) Alzheimer's disease, when such disease is diagnosed as severe or end stage; (M) Acquired immune deficiency syndrome, when such syndrome is diagnosed as severe or end stage; (N) Peripheral neuropathy, when such symptoms are diagnosed as severe or end stage; (O) Post-traumatic stress disorder; resulting from direct exposure to or the witnessing of a trauma for a patient who is at least 18 years of age; or (P) Intractable pain; or (Q) Lupus." PART IV SECTION 4-1. All laws and parts of laws in conflict with this Act are repealed. ## Summaries written by Georgia Commons The following was written by claude-sonnet-5 from the text above and is not part of the bill. Quote the text, not the summary. House Bill 227 would rename 'low THC oil' to 'medical cannabis' throughout Georgia law, adjust related criminal penalties and exemptions, and add lupus to the list of conditions that qualify patients for a medical cannabis registration card. ### Plain-language summary Georgia currently regulates a cannabis derivative called 'low THC oil' under several different chapters of state law, including criminal statutes, the Department of Public Health's patient registry, and the Georgia Access to Medical Cannabis Commission's licensing rules. This bill, called the 'Putting Georgia's Patients First Act,' replaces the term 'low THC oil' with 'medical cannabis' in dozens of Code sections across Titles 2, 16, and 31, and in the tort law governing healthcare provider liability. Beyond the renaming, the bill rewrites the criminal penalty structure for unlawful possession, sale, and trafficking of medical cannabis, updates exemptions for university research programs and licensed businesses, and excludes lawfully possessed medical cannabis from Georgia's Controlled Substances Act. It also directs the Commission to conduct public awareness campaigns about the medical cannabis program, sets rules for how licensees may share product information with doctors and patients, and adds lupus to the list of medical conditions eligible for a medical cannabis registration card under O.C.G.A. § 31-2A-18. ### What it does - Replaces 'low THC oil' with 'medical cannabis' in dozens of Code sections across Titles 2, 16, and 31, and in the tort statute on healthcare provider liability (O.C.G.A. § 51-1-29.6). - Rewrites the criminal penalties in O.C.G.A. § 16-12-191 for possessing, selling, or trafficking medical cannabis without proper registration, keeping tiered fines and prison terms based on quantity. - Excludes lawfully possessed and controlled medical cannabis from the definition of 'marijuana' under Georgia's Controlled Substances Act (O.C.G.A. §§ 16-13-21 and 16-13-25). - Adds a new duty for the Georgia Access to Medical Cannabis Commission to run public awareness and outreach campaigns about the medical cannabis program for patients, law enforcement, and healthcare providers. - Sets rules limiting how licensees can share product information with physicians, patients, and caregivers, banning misleading claims or marketing aimed at children. - Adds lupus to the list of qualifying conditions for a medical cannabis registration card under the Department of Public Health's patient registry (O.C.G.A. § 31-2A-18). ### Who it affects Registered medical cannabis patients and their caregivers, physicians who certify patients, licensed producers and dispensers, the Georgia Access to Medical Cannabis Commission, the Department of Public Health, law enforcement agencies, and university researchers involved in cannabis clinical trials. ### Why it matters Patients and businesses currently dealing with 'low THC oil' rules would see the same substance referred to and regulated as 'medical cannabis,' with updated criminal exemptions and clearer rules on what licensees can tell patients and doctors. Georgians with lupus would newly qualify for a registration card. ### Key provisions - Section 1-1 gives the Act its short title, the 'Putting Georgia's Patients First Act.' - Part II (Sections 2-1 through 2-4) replaces 'low THC oil' with 'medical cannabis' throughout Titles 2, 16, and 31 and in the tort liability statute. - Section 3-1 rewrites Article 8 of Chapter 12, Title 16, updating definitions and setting tiered criminal penalties: misdemeanor for small unauthorized amounts, felony imprisonment of 1 to 10 years and up to $50,000 fine for larger amounts, and trafficking penalties up to 20 years and $1 million for the largest quantities. - Section 3-3 adds a duty for the Georgia Access to Medical Cannabis Commission to conduct public education and outreach about the medical cannabis program. - Section 3-4 rewrites rules on where licensees can operate near schools and churches and how they may share product information with physicians and patients without misleading or child-targeted marketing. - Section 3-5 and 3-6 exclude lawfully possessed medical cannabis and products from the legal definitions of 'marijuana' and Schedule I substances in the Controlled Substances Act. - Section 3-7 adds lupus as a new qualifying condition for a medical cannabis registration card under O.C.G.A. § 31-2A-18. - Section 4-1 repeals any conflicting laws. ## Status - Status: Engrossed (2025-02-27) - Last action: Senate Read and Referred (2025-02-28) - Sponsors: Robert Dickey, Matt Reeves, Brian Prince, Leesa Hagan, Trey Rhodes, Eric Bell - Official page: https://www.legis.ga.gov/legislation/69832 > The history, votes, and amendments (493 characters) are at https://georgiacommons.org/bills/2025-2026/hb227.md?full=1